Patent · US Active

NMDAR antagonists for the treatment of diseases associated with angiogenesis

US10583171B2 · kind B2 · utility

0Cited by

1References

8Claims

0Family size

Assignees

INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
UNIVERSITÉ PARIS-SUD · DE

Inventors

Sylvia Cohen-Kaminsky · Le Plessis-Robinson, FR
Sebastien Dumas · Le Plessis-Robinson, FR
Gilles Bru-Mercier · Le Plessis-Robinson, FR

Key dates

Filing date	Nov 30, 2016
Grant date	Mar 10, 2020
Priority date	—
Expiry date	Nov 30, 2036

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2300/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to an N-Methyl-D-aspartate (NMDA) receptor antagonist, for use in the treatment of diseases associated with angiogenesis such as tumor angiogenesis, ocular neovascular disease, Age-related macular degeneration (AMD).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.